NI202000056A - DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION - Google Patents
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPIONInfo
- Publication number
- NI202000056A NI202000056A NI202000056A NI202000056A NI202000056A NI 202000056 A NI202000056 A NI 202000056A NI 202000056 A NI202000056 A NI 202000056A NI 202000056 A NI202000056 A NI 202000056A NI 202000056 A NI202000056 A NI 202000056A
- Authority
- NI
- Nicaragua
- Prior art keywords
- bupropion
- dosage forms
- enantiomerically enriched
- methods
- pure bupropion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen formas de dosificación de (S)-bupropión enriquecido enantioméricamente o (R)-bupropión enriquecido enantioméricamente. El (S)-bupropión o el (R)-bupropión pueden estar enriquecidos con deuterio o pueden tener abundancia isotópica natural. Estas formas de dosificación pueden administrarse, con la alimentación o en ayunas, para tratar la afección aquí mencionada, para lograr un cierto parámetro farmacocinético de un bupropión o un metabolito de un bupropión, y/o para mejorar los niveles plasmáticos de dextrometorfano.Dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion are described. The (S)-bupropion or (R)-bupropion may be enriched with deuterium or may have natural isotopic abundance. These dosage forms can be administered, fed or fasted, to treat the condition mentioned herein, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and/or to improve plasma levels of dextromethorphan.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI202000056A true NI202000056A (en) | 2021-01-11 |
Family
ID=67688503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI202000056A NI202000056A (en) | 2018-02-23 | 2020-08-21 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3755312A4 (en) |
| JP (3) | JP2021513998A (en) |
| KR (3) | KR20230075531A (en) |
| CN (2) | CN112087999A (en) |
| AU (3) | AU2019223187B2 (en) |
| BR (1) | BR112020017179A2 (en) |
| CA (1) | CA3092076A1 (en) |
| CL (1) | CL2020002166A1 (en) |
| CR (1) | CR20200415A (en) |
| EC (1) | ECSP20060179A (en) |
| IL (2) | IL276871B2 (en) |
| MA (1) | MA51914A (en) |
| MX (2) | MX2020008704A (en) |
| MY (1) | MY202993A (en) |
| NI (1) | NI202000056A (en) |
| NZ (1) | NZ767378A (en) |
| PE (1) | PE20211752A1 (en) |
| SG (1) | SG11202008056SA (en) |
| WO (1) | WO2019165379A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20200415A (en) * | 2018-02-23 | 2021-02-03 | Axsome Therapeutics Inc | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| CR20220119A (en) * | 2019-09-20 | 2022-06-22 | Axsome Therapeutics Inc | DOSAGE FORMS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION |
| US12156914B2 (en) * | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2483499A (en) * | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| EP1575565B1 (en) * | 2003-08-08 | 2010-01-06 | Biovail Laboratories International Srl | Modified-release tablet of bupropion hydrochloride |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US9198905B2 (en) * | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| WO2015095713A1 (en) * | 2013-12-20 | 2015-06-25 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| CR20200415A (en) * | 2018-02-23 | 2021-02-03 | Axsome Therapeutics Inc | Dosage forms and methods for enantiomerically enriched or pure bupropion |
-
2019
- 2019-02-25 CR CR20200415A patent/CR20200415A/en unknown
- 2019-02-25 IL IL276871A patent/IL276871B2/en unknown
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/en not_active Ceased
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/en active Pending
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/en unknown
- 2019-02-25 MA MA051914A patent/MA51914A/en unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 IL IL313368A patent/IL313368A/en unknown
- 2019-02-25 MY MYPI2020004315A patent/MY202993A/en unknown
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/en active Pending
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/en unknown
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/en not_active Ceased
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/en unknown
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/en active Pending
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 CN CN202510967625.3A patent/CN120827545A/en active Pending
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en not_active Ceased
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/en unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/en unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/en unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/en unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521B2/en active Active
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/en active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/en active Pending
- 2024-08-17 AU AU2024205858A patent/AU2024205858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021513998A (en) | 2021-06-03 |
| SG11202008056SA (en) | 2020-09-29 |
| CN120827545A (en) | 2025-10-24 |
| AU2024205858A1 (en) | 2024-09-05 |
| EP3755312A1 (en) | 2020-12-30 |
| MX2023009281A (en) | 2023-08-17 |
| MA51914A (en) | 2020-12-30 |
| CA3092076A1 (en) | 2019-08-29 |
| IL276871B1 (en) | 2024-07-01 |
| AU2022204521B2 (en) | 2024-09-05 |
| IL276871B2 (en) | 2024-11-01 |
| EP3755312A4 (en) | 2022-03-16 |
| KR20230075531A (en) | 2023-05-31 |
| JP2024075655A (en) | 2024-06-04 |
| JP2022153638A (en) | 2022-10-12 |
| IL313368A (en) | 2024-08-01 |
| KR20240091043A (en) | 2024-06-21 |
| BR112020017179A2 (en) | 2020-12-22 |
| KR20210003091A (en) | 2021-01-11 |
| MY202993A (en) | 2024-05-31 |
| AU2019223187A1 (en) | 2020-09-17 |
| NZ767378A (en) | 2024-03-22 |
| AU2022204521A1 (en) | 2022-07-21 |
| CN112087999A (en) | 2020-12-15 |
| IL276871A (en) | 2020-10-29 |
| MX2020008704A (en) | 2020-12-07 |
| CL2020002166A1 (en) | 2020-10-23 |
| PE20211752A1 (en) | 2021-09-06 |
| CR20200415A (en) | 2021-02-03 |
| WO2019165379A1 (en) | 2019-08-29 |
| ECSP20060179A (en) | 2020-12-31 |
| AU2019223187B2 (en) | 2022-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202000056A (en) | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | |
| CL2019001293A1 (en) | Agents, uses and methods for the treatment of synucleinopathy. | |
| MX2016010235A (en) | Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor. | |
| GT201600137A (en) | COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBE AND ROSUVASTATIN | |
| UY36703A (en) | COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF A POLINUCLEOTIDE ON A PLANT | |
| WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| MX2023009631A (en) | Methods of treating seizure disorders and prader-willi syndrome. | |
| CL2019002218A1 (en) | Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease. | |
| BR112018074655A2 (en) | fosnetupitant injectable formulation and method of manufacturing a formulation | |
| CL2020003143A1 (en) | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for the treatment of a parasitic disease | |
| BR112017013532A2 (en) | resin composition | |
| CL2018002200A1 (en) | Combined administration of a penetrating agent and a sulfur compound containing compound for plants. | |
| ECSP22030119A (en) | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | |
| BR112018074434A2 (en) | pharmaceutical compositions comprising safinamide | |
| MX2016014740A (en) | A METHOD FOR THE TREATMENT OF MOVEMENT DISORDERS WITH BEFIRADOL. | |
| MY198201A (en) | A Combination Medicament Comprising Phenylephrine And Paracetamol | |
| MX2020013385A (en) | Methods of modulating tetrabenazine metabolites plasma levels using bupropion. | |
| MY203254A (en) | Pharmaceutical preparation | |
| MX2018010367A (en) | TITULATION OF CEBRANOPADOL. | |
| AR104877A1 (en) | COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF A POLINUCLEOTIDE ON A PLANT | |
| BR112021011755A8 (en) | METHOD TO PROVIDE AN ORAL TREATMENT BENEFIT WITH THE USE OF A LOW SOLUBILITY CALCIUM AND FLUORIDE COMPOUND | |
| UA99842U (en) | The method of anesthesia | |
| AR103766A1 (en) | CONTROLLED RELEASE DOSAGE FORM | |
| DOP2019000199A (en) | ORAL THYROIDAL THERAPEUTIC AGENT | |
| UA122891U (en) | PHARMACEUTICAL COMPOSITION FOR LOCAL ANESTHESIA BASED ON BUPIVACINE AND EPINEPHRINE |